Restrictive Cardiomyopathy Treatment Market - By Treatment (Diuretics, Beta-Blockers, ACE Inhibitors, Antiarrhythmics, Calcium Channel Blocker, Anticoagulants), Route of Administration (Oral, Parenteral), Distribution Channel, Global Forecast, 2023-2032
Published Date: August - 2024 | Publisher: MIR | No of Pages: 240 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationRestrictive Cardiomyopathy Treatment Market - By Treatment (Diuretics, Beta-Blockers, ACE Inhibitors, Antiarrhythmics, Calcium Channel Blocker, Anticoagulants), Route of Administration (Oral, Parenteral), Distribution Channel, Global Forecast, 2023-2032
Restrictive Cardiomyopathy Treatment Market Size
Restrictive Cardiomyopathy Treatment Market size was estimated to be around USD 98.4 million in 2022 and is anticipated to showcase notable growth of CAGR 5.8% during the forecast period. The increasing prevalence of cardiac diseases, growing awareness, and demand for early diagnosis of diseases, advancements in treatment options, growing healthcare expenditure are the key factors contributing to the growth of global restrictive cardiomyopathy treatment.
Restrictive cardiomyopathy (RCM) is a rare heart condition in characterized by the abnormal stiffness of the heart muscles, which causes difficulty for heart to adequately relax and fill with blood. This makes it more difficult for the heart to pump blood efficiently, which impairs cardiac function. The diagnosis of restrictive cardiomyopathy frequently entails the evaluation of a patient's medical history, physical exam, cardiac imaging tests (such as echocardiogram and cardiac MRI), and sometimes cardiac catheterization and biopsy to identify the underlying cause and severity of the condition.
| Report Attribute | Details |
|---|---|
| Base Year | 2022 |
| Restrictive Cardiomyopathy Treatment Market Size in 2022 | USD 98.4 Million |
| Forecast Period | 2023 to 2032 |
| Forecast Period 2023 to 2032 CAGR | 5.8% |
| 2032 Value Projection | USD 172.4 Million |
| Historical Data for | 2018 to 2022 |
| No. of Pages | 122 |
| Tables, Charts & Figures | 214 |
| Segments covered | Treatment, Route of Administration, Distribution Channel, and Region |
| Growth Drivers |
|
| Pitfalls & Challenges |
|
The management of symptoms, improving heart function, and, when possible, addressing the underlying cause are the main goals of treatment for restrictive cardiomyopathy. Depending on the specific patient's health and demands, medications, lifestyle changes, and, in some situations, surgical procedures or a heart transplant are recommended.
COVID-19 Impact
The COVID-19 pandemic put a real damper on how people with restrictive cardiomyopathy got the care they needed. People were scared to go to the doctor or have surgeries that weren't urgent, so many diagnosis and treatments had to be put on hold. And even if they did go to the doctor, hospitals were so busy fighting COVID-19 that they couldn't always give them the same level of care. Not enough doctors and nurses were available, and supplies were running low. So, many people with restrictive cardiomyopathy had to wait longer to get the help they needed.
With the decreasing number of covid-19 cases and restrictions the number of patients visiting hospitals and medical centres for regular check-ups or treatment is increasing leading to the growth of this market.
Restrictive Cardiomyopathy Treatment Market Driving Factors
The increasing prevalence of cardiac diseases is gaining more attention of the medical facilities and increasing public awareness due to which the healthcare providers are becoming more vigilant in diagnosing and treating various cardiac conditions, including restrictive cardiomyopathy. The cardiomyopathy may affect 1 in 500 adults, among all the cardiomyopathy cases, the restrictive cardiomyopathy account for approximately 5% of it.
The restrictive cardiomyopathy is a rare disease and can occur at any age, but it mostly affects the geriatric population. Due to the increasing prevalence of geriatric population worldwide, the prevalence of cardiac diseases, including restrictive cardiomyopathy increases. The restrictive cardiomyopathy is often associated with systemic diseases, such as amyloidosis, sarcoidosis, and hemochromatosis. The prevalence of such diseases also influences the occurrence of restrictive cardiomyopathy. This eventually leads to the increasing demand for diagnosis and treatment of cardiac diseases, including restrictive cardiomyopathy.
Restrictive Cardiomyopathy Treatment Market Analysis
When it comes to treating restrictive cardiomyopathy, doctors have a toolbox of medications at their disposal. These include diuretics, beta-blockers, ACE inhibitors, antiarrhythmics, calcium channel blockers, anticoagulants, and others. The most common choice is diuretics, which make up about a quarter of the market. Why? Because they help reduce fluid buildup in the body. This can make a big difference for people with restrictive cardiomyopathy because it improves their heart's ability to pump blood. Diuretics also help lower blood pressure in the veins, which reduces the pressure in the heart chambers. This makes it easier for the heart to fill with blood and pump it out more efficiently.
Based on route of administration, the restrictive cardiomyopathy treatment market is classified oral and parenteral. The oral segment was valued to be USD 82.6 million in 2022. As restrictive cardiomyopathy requires long-term treatment and management of disease. Oral medications are more convenient and allows for continuous treatment for extended periods. The convenience of taking medications at home without the need for visiting hospital improves the adherence to the prescribed treatment. The oral medications are generally less expensive due to which it is a cost-effective option for long-term treatment.
When it comes to getting treatment for restrictive cardiomyopathy, there are a few main ways to do it. You can go to a hospital pharmacy, which is usually part of a hospital. These pharmacies are set up to handle and give out medications, and many of them are open 24/7. They also have a wide range of medications, which may not be available at a regular pharmacy or online. Another option is a retail pharmacy, which is the kind you might find in a drug store. These pharmacies are more convenient, but they may not have the same range of medications as a hospital pharmacy. Finally, there are other distribution channels, such as online pharmacies or specialty pharmacies. These can be a good option if you need a specific medication that isn't available at other pharmacies. In 2022, hospital pharmacies had the biggest share of the market for restrictive cardiomyopathy treatments. This is because they are well-established and can handle the special needs of these patients. The market is expected to grow by 5% each year over the next few years. This is due to the increasing number of people with restrictive cardiomyopathy, as well as the growing awareness of and demand for treatment.
The North American restrictive cardiomyopathy treatment market is expected to grow at CAGR of 5.3% over the forecast years due to the increasing prevalence of restrictive cardiomyopathy, increasing geriatric population, increasing demand and awareness about early diagnosis and treatment, and availability of advanced treatment options. In addition to this, North America has a well-developed healthcare system, increasing healthcare expenditure, and presence of prominent players in this market. All these factors aid in the market expansion.
Restrictive Cardiomyopathy Treatment Market Share
The key players in the restrictive cardiomyopathy treatment market are
- Pfizer Inc.
- Sanofi
- AstraZeneca
- F Hoffmann-La Roche Ltd.
- Merck and Co. Inc.
- Array Biopharma Inc.
- Capricor Therapeutics
- MyoKardia
- Janssen Pharmaceuticals
- Vericel Corporation
These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches to maintain a competitive edge in the industry.
Restrictive Cardiomyopathy Treatment Industry News
- In February 2020, European Commission approved the VYNDAQEL of Pfizer for treating transthyretin amyloid cardiomyopathy which is leads to restrictive cardiomyopathy. This helped company to boost the revenue and reach untapped markets.
- In May 2019, U.S. FDA approved Pfizer’s VYNDAQEL and VYNDAMAX for restrictive cardiomyopathy. This strengthened the product portfolio of the company and boosted the revenue growth.
The restrictive cardiomyopathy treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments
Click here to Buy Section of this Report
Market Size, By Treatment
- Diuretics
- Beta-blockers
- ACE inhibitors
- Calcium channel blockers
- Antiarrhythmics
- Anticoagulants
- Other treatments
Market Size, By Route of Administration
- Oral
- Parenteral
Market Size, By Distribution Channel
- Hospital pharmacies
- Retail pharmacies/ Drug stores
- Other distribution channels
The above information is provided for the following regions and countries
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- Rest of Middle East & Africa
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy